[{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Podiatry","graph2":"Preclinical","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Innocan Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Innocan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"FibroBiologics","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CYWC628","moa":"Undisclosed","graph1":"Podiatry","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ FibroBiologics","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ FibroBiologics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).

                          Product Name : CYWC628

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 18, 2024

                          Lead Product(s) : CYWC628

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : FibroBiologics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details : Cannabidiol is a topical CB1 receptor negative allosteric modulator (NAM), which is being evaluated in phase 1 clinical studies for the treatment of Diabetic Foot.

                          Product Name : LPT-CBD

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          August 15, 2023

                          Lead Product(s) : Cannabidiol

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details :

                          Product Name : CYP-006TK

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 30, 2021

                          Lead Product(s) : Cymerus Mesenchymal Stem Cell

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AAN
                          Not Confirmed
                          AAN
                          Not Confirmed

                          Details :

                          Product Name : CYP-006TK

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 03, 2021

                          Lead Product(s) : Cymerus Mesenchymal Stem Cell

                          Therapeutic Area : Podiatry

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank